Attention all penny stock enthusiasts! Get ready to add some exciting new stocks to your portfolio! First up, we have EyePoint Pharmaceuticals – a micro-cap biopharma company focused on improving sight through the development and commercialization of treatments for eye disorders. With two products already on the market, Yutiq and Dexycu, and a promising pipeline including EYP-1901 for the treatment of wet AMD, EyePoint is a company to watch. With net product revenue of $9.7 million in 3Q22 and positive results from the Phase 1 DAVIO clinical trial, several analysts are calling it a Strong Buy with room for a potential 1,452% growth in the next 12 months. Next, let’s take a look at Alpha Tau Medical – a biotech company revolutionizing cancer treatment with their Alpha DaRT technology. This precise form of radiation therapy is administered by inserting tiny amounts of radiu-224 into tumor cells, releasing high-energy alpha particles directly into the cancer cells while sparing surrounding healthy tissue. With regulatory approval for clinical trials in Canada and the UK, and several upcoming milestones including trials in Israel and Canada, this early-stage biotech has a solid consensus rating of Strong Buy. With a $18 price target, analysts predict an impressive 460% potential upside for the coming year. Don’t miss out on these exciting opportunities in the penny stock market!
#stocks #stockmarket #stockmarketnews
Join this channel to get access to perks:
FREE MONEY:
1 Free Robinhood stock:
Get 2 Free stocks with Webull when you invest $100 on your first deposit
Disclosure: This video was done by myself, and it expresses my own opinions. This is not investment advice or financial advice and it should not be taken as investment advice or financial advice in any way shape or form. I am not receiving any form of compensation for this video from the company or organization that I am expressing opinions about. This video is for entertainment and or educational purposes only.
SOURCES:
